Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy

Wisconsin Medical Journal

Volumn 107, Issue 7, 2008, Pages 335-338

  Chan, Micah R ^a,b   Yevzlin, Alexander S ^a   Hinshaw, Molly ^a   Jaffery, Jonathan B ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Section of Nephrology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CALCIUM; CEPHALOSPORIN; HYPERTENSIVE AGENT; LANTHANUM CARBONATE; PHOSPHORUS;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; BACTERIAL PERITONITIS; BLOOD VESSEL CALCIFICATION; CASE REPORT; CLINICAL FEATURE; DRUG ERUPTION; ENTERIC FEEDING; ERYTHEMA; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LABORATORY TEST; LIVER TRANSPLANTATION; MALE; NOSE FEEDING; PHYSIOTHERAPY; SEPTIC SHOCK; SKIN BIOPSY; SKIN CALCIFICATION; SKIN DEFECT;

CALCIPHYLAXIS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LANTHANUM; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 56049124630     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bryant JH, White WH. A case of calcification of the arteries and obliterative endarteritis, associated with hydronephrosis, in a child aged 6 months. Guys Hospital Rep. 1898;55:17-20.
2. Selye H. Calciphylaxis. Chicago, IL: University of Chicago Press; 1962.
3. Couto FM, Chen H, Blank RD, Drezner MK. Calciphylaxis in the absence of end-stage renal disease. Endocr Pract. 2006;12:406-410.
4. Campistol JM, Almirall J, Martin E, Torras A, Revert L. Calcium-carbonate-induced calciphylaxis. Nephron. 1989;51:549-550.
5. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002;15:172-186.
6. Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol. 2003;59:463-470.
7. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis. 2001;37:1267-1276.
8. Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltratio using low calcium replacement fluid: case report. Nephrol Dial Transplant. 2005;20:1260-1262.
9. Monney P, Nguyen QV, Perroud H, Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant. 2004;19:2130-2132.
10. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60:324-332.
11. Roe SM, Graham LD, Brock WB, Barker DE. Calciphylaxis: early recognition and management. Am Surg. 1994;60:81-86.
12. Guldbakke KK, Khachemoune A. Calciphylaxis. Int J Dermatol. 2007;46:231-238.
13. Levin A, Mehta RL, Goldstein MB. Mathematical formulation to help identify the patient at risk of ischemic tissue necrosis - a potentially lethal complication of chronic renal failure. Am J Nephrol. 1993;13:448-453.
14. Han MM, Pan J, Shinkai K, Franc B, Hawkins R, Aparici CM. Calciphylaxis and bone scintigraphy: case report with histological confirmation and review of the literature. Ann Nucl Med. 2007;21:235-238.
15. Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005;67:2295-2304.
16. Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant. 2005;20:775-782.